Surprisingly, we could not detect a measurable CD8+ T cell response in tumor-bearing mice against TGAARFDEF, the neoepitope that elicited the strongest tumor rejection (Figure 2A) and a robust CD8+ T cell response in non–tumor–bearing immunized mice (Figure 2E). This evidence concerns the gene CD8A and neoplasm.